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Abstract
Objective: Type 2 diabetes mellitus (DM) accelerates brain aging and cognitive decline. Complex interactions between
hyperglycemia, glycemic variability and brain aging remain unresolved. This study investigated the relationship between
glycemic variability at multiple time scales, brain volumes and cognition in type 2 DM.
Research Design and Methods: Forty-three older adults with and 26 without type 2 DM completed 72-hour continuous
glucose monitoring, cognitive tests and anatomical MRI. We described a new analysis of continuous glucose monitoring,
termed Multi-Scale glycemic variability (Multi-Scale GV), to examine glycemic variability at multiple time scales. Specifically,
Ensemble Empirical Mode Decomposition was used to identify five unique ultradian glycemic variability cycles (GVC1–5) that
modulate serum glucose with periods ranging from 0.5–12 hrs.
Results: Type 2 DM subjects demonstrated greater variability in GVC3–5 (period 2.0–12 hrs) than controls (P,0.0001), during
the day as well as during the night. Multi-Scale GV was related to conventional markers of glycemic variability (e.g. standard
deviation and mean glycemic excursions), but demonstrated greater sensitivity and specificity to conventional markers, and
was associated with worse long-term glycemic control (e.g. fasting glucose and HbA1c). Across all subjects, those with
greater glycemic variability within higher frequency cycles (GVC1–3; 0.5–2.0 hrs) had less gray matter within the limbic
system and temporo-parietal lobes (e.g. cingulum, insular, hippocampus), and exhibited worse cognitive performance.
Specifically within those with type 2 DM, greater glycemic variability in GVC2–3 was associated with worse learning and
memory scores. Greater variability in GVC5 was associated with longer DM duration and more depression. These
relationships were independent of HbA1c and hypoglycemic episodes.
Conclusions: Type 2 DM is associated with dysregulation of glycemic variability over multiple scales of time. These time-
scale-dependent glycemic fluctuations might contribute to brain atrophy and cognitive outcomes within this vulnerable
population.
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Introduction
Type 2 diabetes mellitus (type 2 DM) is among the leading
causes of morbidity, cognitive decline and dementia [1,2]. DM
accelerates signs of brain aging and manifests as regional
hypoperfusion, tissue atrophy and cognitive and functional
impairment [3,4]. Fluctuation of serum glucose between
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hyper- and hypoglycemic levels may exacerbate the risk for
dementia [2,5,6]. Recent clinical trials indicate that interactions
between chronic hyperglycemia and glycemic variability are
complex and that their effects on the brain and cardiovascular
autonomic system are not well understood [7,8].
Glucose metabolism is influenced by numerous intrinsic
rhythms and behaviors, including autonomic, hormonal and
cardiovascular responses to activity, meals and sleep [9–12]. These
regulatory processes often interact and are closely coupled with the
body clock system and central autonomic neural networks,
resulting in complex dynamics of glucose and insulin signaling
between the brain and peripheral organs. Glucose variability is
linked with several ultradian rhythms, e.g., insulin and cortisol
secretion [13–17], autonomic control of sleep cycle and nighttime
blood pressure reduction (i.e., nocturnal dipping) [12,18], meals
and sleep/wake cycles [12,19]. Therefore, serum glucose levels
fluctuate over multiple temporal scales, and alterations of these
regulatory processes may contribute to type 2 DM-related
complications [20,21]. Recent advances in signal processing
allowed to quantify multi-scale fluctuations from a discrete, non-
stationary time-series of serum glucose and therefore may provide
critical insight into the effects of glucose variability on functional
outcomes.
Our objective was to study the effects of glycemic variability at
distinct time scales on the brain and cognition in older diabetic
adults.
We hypothesized that: 1) Type 2 DM alters the regulation of
glucose over multiple scales of time. To test this hypothesis, we
have introduced a novel analytical approach termed Multi-Scale
glycemic variability (Multi-Scale GV), which is based upon the
Ensemble Empirical Mode Decomposition (EEMD) algorithm
[22–24]. This approach, which has no priori assumptions
regarding cycle length, signal linearity or stationarity, enables
identification of the degree of glycemic variability for multiple
unique oscillatory cycles with average periods ranging from
minutes to hours. We have compared Multi-Scale GV measures
to traditional measures of glycemic variability to validate this
approach. Further, we analyzed glycemic variability for entire
recording period, but also separately for day and night periods to
determine whether day-time behaviors affect glycemic variability
at specific time-scales. We further hypothesized that: 2) Increases
in glycemic variability at specific time-scales would be related to
structural changes in central autonomic network and worse
cognitive function. Therefore, we sought the relationships among
glycemic variability and gray matter volumes in central autonomic
network, and cognition. Finally, we hypothesized that: 3) In type 2
DM, observed relationships between glycemic variability, brain
structure and cognitive function would be independent of long-
term glycemic control, e.g., hemoglobin A1C (HbA1c) and the
prevalence of hypoglycemic episodes (,70 mg/dL). Hence, we
studied the relationship between glycemic variability, brain
structure and cognitive function in older adults with type 2 DM
and age-matched controls.
Research Design and Methods
Ethics Statement
Experiments were conducted in the Syncope and Falls in the
Elderly Laboratory at the Clinical Research Center and the
Center for Advance Magnetic Resonance Imaging (MRI) at Beth
Israel Deaconess Medical Center (BIDMC). Participants were
recruited consecutively and provided informed written consent as
approved by the Institutional Review Board (IRB, i.e., the
Committee on Clinical Investigations, Beth Israel Deaconess
Medical Center). The study has been approved by BIDMC IRB
and consent forms are available upon request.
Subjects
The cohort consisted of 43 volunteers with type 2 DM aged 50–
85 years, and 26 non-diabetic, age-, sex- and cardiovascular risk-
matched adults with normal fasting glucose and HbA1c.
Recruitment was completed via community advertisement.
Subjects in DM group were diagnosed with type 2 DM and
treated .5 years with oral agents and/or combinations with
insulin, either normotensive (BP,140/90 mm Hg and no medical
history of hypertension) or hypertensive (BP.140/90 mm Hg
and/or treated for hypertension). Control subjects were – normal
glucose, HBA1c, MMSE, with and without hypertension.
Type 2 DM subjects were treated with insulin (11), oral glucose-
control agents (sulfonylurea, second generation agents or their
combinations (34)), or diet (5), and for hypertension (7) and
hyperlipidemia (27). Controls were treated for hypertension (9)
and/or hyperlipidemia (11).
Exclusion criteria were: type 1 DM, history of stroke, subacute
myocardial infarction, significant cardiac diseases, arrhythmias
and nephropathy, kidney or liver transplant, congestive heart
failure, carotid artery stenosis, neurological or other systemic
disorders, dementia or sub-threshold Mini Mental Status Exam
(MMSE) scores ($3 points below the comparative normal value
for the subject’s age group and education level, or #24), current
recreational drug or alcohol abuse, morbid obesity (BMI$40),
claustrophobia, or 3T MRI-incompatible metal implants, pace-
makers or arterial stents.
Of 130 participants (including 74 type 2 DM subjects and 56
control subjects), 30 type 2 DM subjects and 26 control subjects
were excluded. Besides, 5 eligible subjects were also excluded from
the analysis due to incomplete continuous glucose monitoring
(CGM) recordings.
Protocol
CGM and 24-hour ambulatory blood pressure monitoring
(ABPM) [25] were assessed for three days prior to an overnight
admission to the BIDMC Clinical Research Center. A nurse set up
CGM and also trained participants to manually measure their BP
and glucose, four times daily (i.e., before meals and at bed time),
using arm cuff and finger stick methods. Participants were directed
to go to bed at 10pm, wake at 7am and maintain their typical
activities. They documented sleep/wake times, meals and medi-
cations in a diary. Upon admission, neurological and neuropsy-
chological assessments were performed. A fasting blood draw and
urinary sample were obtained the next morning for routine
glucose, lipid and renal panels. The MRI was then completed.
Continuous Glucose Monitoring
The iPro Professional CGM (Medtronic, Minneapolis MN)
enabled multi-day glucose measurements with a waist-level
subcutaneous sensor [26]. The sensor obtained interstitial glucose
levels every five minutes and was calibrated four times daily via
finger stick [27].
Neuropsychological Measures
Neuropsychological assessments included the Mini-Mental State
Examination (MMSE), Hopkins Verbal Learning Test–Revised
(HVLT, verbal learning and memory function, including a Total
Recall (total number of list items learned across trials), Delayed
Recall (total number of list items recalled after the delay),
Retention (percentage of items from Total Recall that are
Glycemic Variability in Type 2 Diabetes
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subsequently recalled on Delayed Recall), and Recognition
Discrimination Index (number of list items correctly identified
among non-list items)) [28], Rey-Osterreith Complex Figure Test
(ROCFT, a measure of visual-spatial ability and visual memory
function, including Immediate Recall and Delayed Recall), Trail
Making Test A and B (TMT, executive function), and Verbal
Fluency (a measure of executive function, dependent variables for
the fluency measures include number of items generated for each
of three phonemic trials (e.g., F, A, S) and the number of items
generated for the semantic task (e.g., animals)) [29]. The Geriatric
Depression Scale (GDS) and the Instrumental Activities of Daily
Living (IADL) Scale were also completed. The neuropsychological
test results were analyzed using age-adjusted standardized T
scores.
Composite cognitive performance for learning and memory
function (‘‘learning and memory T score’’) was calculated as an
average of HVLT and ROCFT T scores. Composite cognitive
performance for executive function (‘‘executive function T score’’)
was calculated as an average of Verbal Fluency and TMT T
scores. A total composite cognitive function (‘‘Composite T score’’)
was calculated as the average of all the T scores [30]. All the T
scores were adjusted for age, sex, race and educational levels.
Magnetic Resonance Imaging
Studies were performed on a 3-Tesla GE GHX MRI scanner
using a quadrature and eight-channel phase array head coils (GE
Medical Systems, Milwaukee, WI). Anatomical images were
acquired using 3-D magnetization prepared rapid gradient echo
(MP-RAGE) and fluid attenuated inversion recovery (FLAIR)
sequences. Images were analyzed using tools developed in
interactive data language (IDL, Research Systems, Boulder,
Colorado, USA) and MATLAB (MathWorks, Natick, Massachu-
setts, USA). Anatomical MR images (MP-RAGE and FLAIR)
were co-registered non-linearly to the MNI152 standard template
and segmented to calculate regional gray and white matter and
cerebrospinal fluid volumes in main anatomical lobes and their
sub-regions (SPM, University College London, UK) [31]. Sub-
regions were defined according to the LONI Probabilistic Brain
Atlas (LPBA40). Each lobe (e.g. frontal, temporal etc.) was divided
according to anatomical divisions and structures (e.g. middle
orbitofrontal gyrus, superior frontal gyrus, hippocampus, etc.).
Glycemic Variability Measurements
Glycemic variability was calculated from the entire 72-hour
CGM time-series. Traditional metrics included the standard
deviation (SD), mean glycemic excursions (MAGE) [32] and the
number and duration of hypoglycemic episodes defined as
glycemic levels ,70 mg/dL. MAGE was calculated as the
arithmetic mean of glucose increases or decreases (from glucose
nadirs to peaks or vice versa) when both ascending and descending
segments exceeded the value of one SD of mean glucose [32].
To study glycemic variability at multiple temporal scales, we
propose a new measurement called Multi-Scale Glycemic Vari-
ability (Multi-Scale GV). This technique decomposes the original
CGM time-series using EEMD. This adaptive data analysis
technique automatically identifies periodicities intrinsic to the
time-series, which underlie its fluctuations at different time-scales.
It does not assume linearity or stationarity of the series, thereby
offering advantages over traditional approaches such as Fast
Fourier Transform (FFT) or wavelet decomposition [33,34]. Each
CGM time-series was decomposed into multiple new time-series,
termed intrinsic mode functions (IMFs), characterized by a
dominant frequency band. We refer to each IMF as a glycemic
variability cycle (GVC). Thus, Multi-Scale GV enables the
identification and subsequent quantification of GVCs at multiple
time scales from minutes to hours without any priori assumptions
of cycle duration.
Multi-Scale Glycemic Variability Measurement based on
EEMD Algorithm
Computational Steps for Multi-Scale GV analyses are described
as follows:
Step 1. Decompose the raw CGM data (72 hours) of each subject into
IMFs, here referred as glycemic variability cycles (GVCs). Each GVC
consists of narrow-band frequency-amplitude modulations. The
GVCs were obtained via EEMD, which is a noise-assisted
improvement of the EMD method [22,23,35,36], briefly intro-
duced in Text S1.
Step 2. Calculate the average period (time-scale) of each GVC. As CGM
sampling frequency was 5 minutes and sampling duration was 72 hours, we
selected the GVCs with period less than 24 hours. GVCs are non-
stationary, with varying amplitude and frequency. The calculation
of the average period for each GVC is shown in Text S2.
Step 3. For each subject, quantify the glycemic variability at multiple cycles
(or time-scales) by calculating the standard deviation for each GVC obtained in
Step 2.
Statistical Analysis
All variables were summarized using descriptive statistics and
compared between groups using one-way ANOVA and non-
parametric tests.
To test our first hypothesis that type 2 DM alters the regulation
of glucose over multiple scales of time, we compared all markers of
glycemic variability between groups using one-way unadjusted
ANOVAs, and between day and night using two-way ANOVA.
To compare Multi-Scale GV to traditional glycemic measures
(SD and MAGE), we used least square models adjusted for age, sex
and group. Receiver operating curves (ROC) were used to
compare the sensitivity and specificity of Multi-Scale GV, SD
and MAGE.
To test our second hypothesis that increases in glycemic
variability at specific time-scales would be associated with brain
tissue atrophy and cognitive function, we first adjusted cognitive
test scores for age, sex and education. A correlation matrix was
initially used to determine associations among multiple variables
(age, sex, regional MR volumes and cognitive). Those correlations
with r2.0.1 and P,0.05 were included in the modeling approach.
Least squares models were then used to assess the relationships
between glycemic variability and outcome measures. Independent
variables were GVCs, SD and MAGE, and dependent variables
were regional brain volumes and cognitive functional measures.
These models were calculated for each parameter separately to
minimize repeated measures effects. In results section, we
presented r2 adjusted for co-variants. For the relationship between
Multi-Scale GV and brain volumes, we conservatively selected
only models with adjusted r2.0.25, and P,0.05 from models
adjusted for age, sex, group.
To test our third hypothesis that observed relationships between
glycemic variability, brain structure and cognitive function would
be independent of long-term glycemic control (i.e., fasting glucose,
HbA1c, DM duration, hypoglycemic episodes), least squares
models were first used to assess the relationships between HbA1c
(or hypoglycemic episodes), brain volumes and functional
outcomes, then used to assess the relationship between glycemic
variability, brain volumes and functional outcomes. Models were
adjusted for age, sex, group, glucose, HbA1c and hypoglycemic
episodes. We also examined the relationship between HbA1c, SD,
Glycemic Variability in Type 2 Diabetes
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MAGE and brain volumes, functional outcomes, using least
squares models adjusted for age, sex and group.
The effects of diabetes duration, medication classes, BP,
hypertension, HbA1c, body mass index and other confounders
were also evaluated.
All the relationships were assessed using least squares models
adjusted for age and sex (and group for all subjects), and we
presented r2 for the entire model and P values for the specific effect
of Multi-scale GV.
Results
Characteristics of the Study Cohort
Table 1 summarizes cohort demographics, cardiovascular and
metabolic outcomes, cognition and global brain volumes. There
were no between-group differences in age, sex, education, 24 hour
systolic and diastolic BP, reduction of diastolic BP during sleep,
average number or duration of hypoglycemic events, depression,
Trail Making Test, MMSE score, or global CSF. As compared to
controls, the type 2 DM group had lower body mass index, HbA1c
and fasting glucose. This group also exhibited worse composite
Table 1. Characteristics of the study cohort.
Diabetes (n =43) Control (n = 26) P-value
Demographics
Age (years) 65.5268.73 65.21610.23 0.89
Sex (male, female) 20, 23 14, 12 0.56
Body mass index (kg/m2) 29.9264.90 25.2064.63 ,0.0001
Race (W, AA, Latino, other) 28, 12, 2, 1 25,1, 0, 0 0.032
Education (years) 15.1763.62 15.9263.02 0.33
Cardiovascular and Metabolic Outcomes
Hypertension (yes/no) 35/43 7/26 ,0.0001
24 hour systolic BP (mmHg) 131.2169.47 126.9268.50 0.08
24 hour diastolic BP (mmHg) 67.7367.31 67.4068.81 0.89
Microalbumin, urine (ug/mL) 11.94616.35 19.16633.22 0.56
Cholesterol-to-HDL ratio 3.8062.64 3.1861.03 0.34
Triglycerides (mg/dL) 139.23687.01 105.30659.02 0.03
Total number of Hypoglycemic Events 1.8062.80 4.0065.80 0.29
Average duration of Hypoglycemic Events (min) 46.45630.75 53.69633.76 0.52
Diabetes duration (years) 13.3366.81 - -
Hematocrit (%) 39.8068.23 40.1663.62 0.06
Hemoglobin A1C (%) 7.1661.17 5.6660.29 ,0.0001
Hemoglobin A1C (mmol/mol) 54.7612.8 38.263.2 ,0.0001
Fasting Glucose (mg/dL) 125.67647.32 89.83610.09 0.0002
Cognitive Outcomes
Composite ‘‘Learning and Memory T score’’ 43.4469.40 51.3569.18 0.0004
- Hopkins Verbal Learning (T Score) 44.1669.44 52.6567.93 ,0.0001
- Rey-Osterrieth Complex Figure Test (T score) 42.26611.22 48.39613.43 0.03
Composite ‘‘Executive function T score’’ 40.8467.60 49.7567.70 ,0.0001
- Verbal Fluency (T score) 37.2267.72 51.6169.26 ,0.0001
- Trail Making Test (T score) 44.5669.93 47.7869.07 0.15
Overall ‘‘Composite T score’’ 42.2067.06 51.4367.27 ,0.0001
MMSE Scores (range: 25–30) 28.4661.54 29.0061.52 0.17
Instrumental Activities of Daily Living 26.1961.31 26.0063.04 0.74
Geriatric Depression Scale 7.1261.14 4.8361.39 0.21
Global Brain Volumes (cm3)
Gray matter 622.16672.96 666.62674.83 0.02
White matter 422.63657.44 461.43657.81 0.01
Cerebrospinal Fluid 611.786206.53 647.516211.05 0.51
Data are presented as mean6 standard deviation (SD). P values were obtained by One-Way ANOVA to compare group means and using Wilcoxon Test for not normally
distributed variables. The variables analyzed using Wilcoxon Test are Age, Sex, Race, Education, Hypertension, Microalbumin (urine), Cholesterol-to-HDL ratio,
Triglycerides, Total number of Hypoglycemic Events, Average duration of Hypoglycemic Events, and Hematocrit, and other variables were analyzed using One-Way
ANOVA. MMSE: Mini-Mental State Examination.
doi:10.1371/journal.pone.0086284.t001
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cognitive function T scores, lower HVLT and ROCFT perfor-
mance (indicating impaired learning and memory).
Multi-Scale Glycemic Variability (Multi-Scale GV)
Multi-Scale GV identified serum glucose fluctuations at five
unique frequencies in type 2 DM subjects and controls: GVC1
(,0.5 hour), GVC2 (,1 hour), GVC3 (,2 hours), GVC4 (4–
5 hours), GVC5 (9–12 hours) (Table 2). The period of GVC4 (type
2 DM: 4.7561.14 hours; controls: 3.8461.05 hours) coincides
with meal cycles as reported in home diaries (type 2 DM:
4.4161.17 hours; controls: 3.9961.35 hours) and the period of
GVC5 (9–12 hours) may reflect sleep/wake cycle. Fig. 1 provides
an example of this technique as applied to the data of a
representative control subject alone (Fig. 1A), as well as in
comparison with an age-matched patient with type 2 DM (Fig. 1B).
As compared to controls, the type 2 DM group had greater
variability in GVC3–5 (P,0.0001) and longer cycle durations in
GVC4 (P=0.004) and GVC5 (P,0.0001). We also separately
analyzed the effects of sleep/wake behavior on glycemic variability
(Fig. 2). GVC1–5 was identified during both day and night in both
groups, but the variability was greater in the DM group. Type 2
DM subjects had greater variability than controls both during the
day (GVC2–5, P=0.00001–0.031) and night (GVC3–5, P,0.0001).
In the type 2 DM group, variability was less at night as compared
to day (GVC2, P=0.002; GVC3–4, P,0.0001). In controls,
variability was less at night as compared to day only in GVC3
(P=0.028).
Relationships between Multi-Scale GV, Conventional
Markers of Glycemic Variability and Long-Term Glycemic
Control
All conventional markers of glycemic variability were greater in
diabetic subjects as compared to controls (Table 2) (e.g. SD,
MAGE of CGM data, and mean, SD of glucose values obtained
from subject-recorded finger sticks) (P,0.0001).
The degree of variability within each GVC correlated with
SD of CGM (r2=0.46–0.89, P,0.005) (Fig. 3A), MAGE
(r2=0.50–0.90, P,0.0004) (Fig. 3B) and both the average and
SD of glucose values measured by finger sticks during home
monitoring (r2=0.32–0.62, P,0.01). However, using an area
under the curve (ROC) analysis, GVC4–5 performed better at
classifying diabetic and control subjects (larger area and higher
sensitivity and specificity) than either SD or MAGE (Fig. 3C).
Across all subjects, greater variability within one or more GVCs
was also associated with worse glycemic control, including higher
fasting glucose (r2=0.31–0.34, GVC1–5 P=0.0006–0.036), higher
HbA1c (r2=0.45–0.50, P,0.05) (Fig. 3D). In the type 2 DM
group, greater variability within GVC5 was associated with longer
type 2 DM duration (r2=0.26, P=0.033), however, no measure of
glycemic variability correlated with the number or duration of
hypoglycemic episodes (defined as glycemic levels ,70 mg/dL).
Relationship between Multi-Scale GV and Brain Volumes
As compared to controls, subjects with type 2 DM had lower
global gray matter (GM, P=0.02) and white matter (WM,
P=0.01) volumes, but not cerebrospinal fluid (CSF) volume
(Table 1). Regionally, diabetic subjects exhibited reduced GM
within the hippocampus, insular cortex, superior parietal gyri and
supramarginal gyri (P,0.05) (Fig. 4, and Fig. 5).
The presented relationships between Multi-Scale GV and
regional brain volumes were got from least squares models for
the entire cohort, as well as within each group separately.
Across all subjects, greater glycemic variability within higher
frequency cycles (GVC1–2, 0.5–1 hours) was associated with lower
GM volumes (r2=0.26–0.74, P=0.001–0.048) and more CSF
volume (r2=0.25–0.50, P,0.05) in multiple regions within the
limbic system, as well as several temporal and parietal regions
linked to learning and memory, e.g. bilaterally within the cingulate
gyrus, hippocampus, middle temporal gyrus, inferior temporal
gyrus and insular cortex, as well as within the left superior parietal
gyrus and right fusiform gyrus (Fig. 4, Fig. 5 and Fig. 6).
In the type 2 DM group only, greater variability in GVC2 was
correlated with lower GM volumes within the cingulate gyrus
(r2=0.40, P=0.02) and insular cortex (r2=0.33, P=0.032).
Table 2. Comparisons of glycemic measures and glycemic variability measures between diabetic and control groups y.
Glycemic variability (mg/dL) Diabetics (n=43) Controls (n =26) P-value
Home monitoring-finger stick glucose 148.06634.92 102.18610.04 ,0.0001
SD of glucose finger stick measurements 44.99628.84 14.6665.48 ,0.0001
Mean CGM glucose value 150.14632.52 107.97616.91 ,0.0001
SD (Standard deviation) 38.39621.73 17.4468.12 ,0.0001
MAGE (Mean Glycemic Excursions) 95.22655.39 39.45616.49 ,0.0001
Multi-Scale GV GVC1 period (hour) 0.6360.03 0.6260.07 0.51
Variability 2.6261.63 1.9961.01 0.08
GVC2 period (hour) 0.8660.12 0.9060.07 0.1
Variability 4.5362.3 3.5261.62 0.055
GVC3 period (hour) 1.9260.41 1.9260.17 0.99
Variability 8.5663.04 4.8362.45 ,0.0001
GVC4 period (hour) 4.7561.14 3.8461.05 0.004
Variability 14.7667.68 5.7263.03 ,0.0001
GVC5 period (hour) 11.3062.38 8.5462.73 ,0.0001
Variability 19.48612.56 6.6863.66 ,0.0001
Data are presented as mean 6 SD and were calculated from 72 hour recordings. P values were obtained by One-Way ANOVA. SD: standard deviation; CGM: continuous
glucose monitoring; Multi-Scale GV: Multi-Scale glycemic variability; GVC: glycemic variability cycle.
doi:10.1371/journal.pone.0086284.t002
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Figure 1. The Multi-Scale Glycemic Variability method applied to 3-day continuous glucose monitoring (CGM). The decomposition is
based on the EEMD (Ensemble Empirical Mode Decomposition) technique. (A) The original CGM time-series from a representative control subject
(male, 72 years old, HbA1c= 5.2%, SD (standard deviation) = 10.44, MAGE (mean average glycemic excursions) = 31.61) is decomposed into five
glycemic variability cycles (GVCs) that are each characterized by fluctuations within a specific frequency band. The bold black lines along the X-axis
denote sleep periods defined by actigraphy and patient records. (B) Comparison of raw CGM signals and selected GVCs between the control subject
in (A) and a representative patient with type2 DM (male, 62 years old, HbA1c= 9.4%, SD=71.36, MAGE= 161.85). The shading areas denote sleep for
the type 2 DM patient, while the bold black lines along the X-axis denote sleep for the control subject.
doi:10.1371/journal.pone.0086284.g001
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However, we also found that higher glycemic variability of GVC3
associated with greater GM in supramarginal gyrus and angular
gyrus (r2=0.41–0.45, P=0.01–0.04).
In the control group only, the degree of variability within
GVC3–5 associated with more CSF within the hippocampal gyrus
(r2=0.40–0.48, P,0.02) and lingual gyrus (r2=0.44–0.47,
P=0.02–0.04). Greater variability of GVC5 was associated with
larger GM volume of the subcortical motor nuclei (caudate
nucleus, r2=0.30–0.33, P,0.03). However, we also found that
higher glycemic variability of GVC3 associated with greater GM
in middle orbitofrontal gyrus (r2=0.29, P=0.048).
HbA1c, fasting glucose, SD and MAGE were not independently
associated with brain volumes and functional outcomes after
controlling for GVC variability measures.
Relationship between Multi-Scale GV and Cognitive
Function
The presented relationships were for the entire cohort, as well as
for DM group and control group separately.
In the entire cohort, greater glycemic variability in GVC2,3,5
was associated with worse learning and memory function (i.e.
HVLT T score, ROCFT T score, and the composite ‘‘learning
and memory T score’’, r2=0.27–0.34, P=0.011–0.036). Greater
glycemic variability in GVC2,5 was associated with worse overall
composite cognitive performance (i.e. ‘‘Composite T score’’,
r2=0.45–0.46, P,0.02). T scores related to executive function
measures, such as TMT T score, verbal fluency T score, and
‘‘executive function T score’’, were not significantly correlated
with Multi-Scale GV.
In type 2 DM group only, greater glycemic variability in
GVC2,3 was associated with worse learning and memory function
(i.e. ‘‘learning and memory T score’’, r2=0.28–0.37, P,0.03),
greater variability in GVC2 was also associated with worse overall
cognitive performance (i.e. ‘‘Composite T score’’, r2=0.44,
P=0.02) and greater variability in GVC5 was associated with
more depression (i.e. GDS, r2=0.18, P=0.014).
No significant relationships between Multi-Scale GV and
cognitive function were found in control group (r2,0.13, P.0.05).
We also analyzed nonparametric multivariate correlations
among glycemic variability, gray matter atrophy and cognition.
Across all subjects, greater variability of GVC2 was associated with
both lower GM volume in cingulate gyrus (r2=0.38–0.40,
P=0.014–0.047) and worse cognitive performance (i.e. ‘‘Compos-
ite T score’’, r2=0.46, P=0.018) (Fig. 6 C and D), and worse
scores on HVLT (r2=0.42–0.46, P=0.002–0.006). Combined
effects of greater variability in GVC2, lower GM in cingulate gyrus
and longer DM duration were highly associated with more
depression (r2=0.69, P,0.02).
Discussion
This study evaluated the complex relationships between
glycemic variability, brain volumes and functional outcomes in
older adults with and without type 2 DM. It determined that time-
specific glycemic fluctuations may be independently associated to
brain atrophy and worse cognitive performance.
We applied a novel EEMD-based approach to quantify
glycemic variability at multiple time scales. The EEMD method
identifies dominant cycles without a priori assumptions about their
periods and is therefore suitable for nonlinear and non-stationary
signals such as continuous monitoring of glycemic levels monitor-
ing. Multi-Scale GV determined that glucose levels fluctuate at five
distinct frequencies (GVC1–5; period 0.5 to 12 hours) in both
diabetics and controls. The GVCs frequencies coincide with one
or more ultradian rhythms that modulate glucose levels. For
example, the periods of GVC1–3 (0.5–2 hrs) correspond to
established autonomic rhythms, cardiovascular and neuroendo-
crine rhythms (insulin and glucocorticoids) [13–17] and certain
aspects of the sleep cycle (i.e. rapid and non-rapid eye movement)
[12]. The period of GVC4 (4–5 hours)) coincides with meal cycles
as reported in home diaries and the period of GVC5 (9–12 hours)
may reflect sleep/wake cycle. Type 2 DM subjects had greater
glycemic variability as compared to controls in GVC3–5, as well as
longer cycles that tended to be even lengthier in type 2 DM
subjects with higher HbA1c levels.
To resolve the complex effects of glycemic variability on brain
volumes and cognitive function, we studied the relationship
between Multi-Scale GV, regional brain volumes and cognition.
We observed that GVCs at specific frequencies were related to
different regional brain volumes and functional outcomes, and that
these relationships were independent of HbA1c, hypoglycemic
episodes, age and sex.
Glucose metabolism is closely coupled with the autonomic
nervous system via oscillating neural networks and particularly
beta-adrenergic and cholinergic systems in the brain, controlling
regional perfusion during spontaneous brain activity, cognitive and
motor tasks. The complex interplay between glucose, neuroendo-
crine and autonomic rhythms is controlled by a system comprising
a central pattern generator (suprachiasmatic nucleus of the
hypothalamus, SCN) and central autonomic network through
complex feedback mechanisms insulin secretion, glucose absorp-
tion and energy expenditure [37,38].
Greater variability in GVC1–3 (0.5–2.0 hours) were strongly
associated with gray matter atrophy affecting the limbic system,
insular cortex, hippocampus and cognitive and visuospatial
orientation circuits within the temporal and parietal lobes. These
associations are clinically relevant because they indicate a link
between glycemic variability and altered central autonomic
Figure 2. Day and night Multi-Scale Glycemic Variability in
older adults with and without type 2 DM As compared to
controls, the type 2 DM group had greater variability during
the day in GVC2–5, and night GVC3–5. At night, glycemic variability
declined in type 2 DM in GVC2–4 and in controls in GVC3. ‘*’ (P= 0.002)
and ‘`’ (P,0.0001) indicate significant differences between diabetics/
day and controls/day; ‘II’ (P,0.0001) indicates significant differences
between diabetics/night and controls/night; ‘{’ (P= 0.003) and ‘1’
(P,0.0001) indicates significant differences between diabetics/day and
diabetics/night; ‘"’ (P= 0.028) indicates significant difference between
control/day and control/night. All the P values were obtained by
ANOVA. Results are presented as mean 6 SEM.
doi:10.1371/journal.pone.0086284.g002
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regulation that translates into adverse functional outcomes. These
regions belong to the limbic system and central autonomic
networks, also known as the ‘‘central command’’ to the
sympathetic and parasympathetic control of heart rate and blood
pressure, gastrointestinal system etc., as well as, selective attention
and emotional arousal processes, and mood. Greater variability in
GVC1–3 was associated with lower gray matter volume in circuits
for learning and controlling memory (cingulate gyrus, hippocam-
pus), visuospatial processing (superior parietal and fusiform gyrus)
motor function and gait (inferior temporal gyrus). In type 2 DM
group specially, greater glycemic variability in GVC2–3 was
associated with worse learning and memory. In contrast, positive
relationships between gray matter and glycemic variability in
controls may suggest regional compensatory activity needed to
maintain glycemic variability in a dynamic stable range.
There is also evidence that brain atrophy is accelerated by type
2 DM [3,4]. Such atrophy manifests preferentially within fronto-
temporo-parietal regions and is associated with cognition and gait
abnormalities [39]. We report that glycemic fluctuations at specific
frequencies, yet not hypoglycemic episodes, have distinct effects on
gray matter volumes in specific regions. Traditional measures such
as hypoglycemic episodes, HbA1c, SD and MAGE did not
correlate with brain atrophy. In addition, separating day and night
time, the associations between Multi-Scale GV and brain volumes
were stronger at night than during day.
The low frequency GVC4 coincided with food intake (,4–
5 hours) as confirmed by home diaries. Yet, GVC4 fluctuations
were also present during the night, suggesting an underlying
intrinsic regulation of eating patterns. Variability in GVC4
increased with higher HbA1c and correlated with SD and MAGE
calculated from CGM. Sleep/wake behavior is reflected in GVC5
mode (,9–12 hours). Notably in diabetics, greater variability in
GVC5 was associated with longer DM duration and more
depression. Multi-Scale GV was more sensitive and specific than
SD and MAGE, indicating that these traditional measures may
not capture the complex impacts of variability that occurs at
specific time scales. An observational study suggested that
reduction in SD and MAGE was associated with better glycemic
control without increase in hypoglycemic events [40]. In the
present study, hypoglycemic episodes, which are commonly
viewed as a barrier to successful glycemic control, were not
associated with specific GVCs, brain atrophy or functional
abnormalities.
Our findings suggest that Multi-Scale GV in type 2 DM is
associated with worse learning and memory functions but not with
executive functions. These results are consistent with population
based studies that identified type 2 DM affects specific cognitive
abilities, namely processing speed and specific types of memory
[41,42]. Type 2 DM associated with slower processing speed and
impaired semantic memory, but not with episodic or working
memory [41], suggesting cognition may reflect a vascular process
combined with insulin resistance in the brain. Our composite
measure of memory reflects verbal and visual-spatial memory.
Hyperglycemia-induced insulin resistance and small vessel disease
Figure 3. Relationships between the fourth glycemic variability cycle (GVC4) and conventional measures of glycemic control. The
degree of glycemic variability within GVC4 was highly correlated with SD (A) and MAGE (B), but the areas under the curves of GVC4 and GVC5 were
greater than SD and MAGE (C). The degree of glycemic variability within GVC4 was highly correlated several markers of glucose control including
HbA1c (D). As with GVC4 (the cycle linked with meal intake), the example in this figure, similar relationships were observed for all other GVC cycles.
The r2 and P values represent the least square model fit.
doi:10.1371/journal.pone.0086284.g003
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is a common pathway for abnormal blood brain barrier (function,
neurovascular coupling, regional vasoreactivity and hypoperfusion
[43–45] and neurotoxicity [46] and neuron-astrocyte signaling),
which are key processes involved in memory formation.
However, the exact mechanisms by which type 2 DM leads to
cognitive decline requires further investigation, notably because a
strict glycemic control did not improve cognitive function
(ACCORD-MIND) in a population study. Indeed, type 2 DM is
associated with an increased risk of both vascular dementia and
Alzheimer’s disease [47], although there is evidence suggesting
that the association may be stronger for Alzheimer’s disease with
cerebrovascular disease.
There was no association between cognitive performance and
glycemic variability in control group, while in the type 2 DM
Figure 4. The brain regions associated with Multi-Scale GV. Higher glycemic variability of GVC1–3 (period 0.5–2 hours) were associated with
lower gray matter (GM) volume (red color; both hemispheres in the cingulate gyrus, hippocampal gyrus, middle and inferior temporal gyrus, insular
cortex, the left superior parietal gyrus and right fusiform gyrus), greater GM volume (blue color; the bilateral supramarginal gyrus, left angular gyrus
and left middle orbitofrontal gyrus), and greater cerebrospinal fluid (CSF) in the right lingual gyrus (green color).
doi:10.1371/journal.pone.0086284.g004
Figure 5. Group differences of regional GM volumes in left hemisphere and their relationship with Multi-Scale GV. ‘*’ indicates
significant differences between the type 2 DM group (white) and controls (grey) in GM volumes (One-Way ANOVA); regional GM volumes in left
hemisphere were correlated with Multi-Scale GV for diabetics and/or controls, blue indicates positive correlation, red indicates negative correlation
with each GVC, G’ = gyrus, ‘#’ indicates we found similar relationship between Multi-Scale GV and GM volumes in the right hemisphere (r2= 0.26–074,
P,0.05). The bar graphs are presented as mean 6 SEM.
doi:10.1371/journal.pone.0086284.g005
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group there was an association. This might be because of the
differences in cognitive function of the two groups. The lower
cognitive function of those with diabetes might be suggestive of
incipient dementia. The stronger association between cognition
and glycemic variability may be due to subjects with type 2 DM
having a greater variety of pathologies in addition to the neural
differences. For example, cardiovascular diseases are more
prevalent in persons with diabetes. Glycemic variability was
associated with memory but not with executive functions, which
has been consistently associated with cerebrovascular disease.
Multi-Scale GV allows us to overcome limitations of traditional
measures and to study effects of glycemic variability at specific
frequencies, and to thus better understand this phenomenon.
Multi-Scale GV provides information about physiological rhythms
that modulate serum glucose at specific time scales and affect
signaling among multiple organ systems. Our current observations
suggest that GVCs at multiple time-scales may be related to
intrinsic rhythms, generated by central pattern generator(s), and
also modulated by behavior factors (meals and/or sleep). Diabetes
alters the cycle length and amplitude of these oscillations, as well as
their relationship to physiological rhythms. These long-term
alterations in brain structural networks appear to manifest as
functional decline. Therefore, this novel approach has indicated
that variability associated with several ultradian rhythms is linked
to regional brain atrophy and worse functional measures,
independent of HbA1c levels and hypoglycemic episodes. This
study thus provides support for the use of Multi-Scale GV to
understand, monitor and develop diagnostics and therapeutics for
treating glycemic variability independently of average glycemic
indices. Glucose metabolism is influenced by numerous intrinsic
rhythms and behaviors. There are likely many other elements in
this complex multi-scale dynamic system of interactions as well,
which highlight the importance of using analyses of variability in
blood glucose levels across multiple temporal scales without the
assumptions of linearity and stationarity. However, making casual
inferences about the direction of influence between the elements in
this complex system is difficult. Diabetes-related disruption of this
complex system may manifests in multi-scale temporal glycemic
variability and specific structural changes in the brain through
complex dynamics not fully accounted for in the current
investigation (one of many possibilities being mutli-scale temporal
variability in circulating insulin levels).
Figure 6. Examples of least squares models indicating negative relationships between Multi-Scale GV and regional GM volumes as
well as cognitive performance. (A) relationship between GVC2 and GM volume in the left insular cortex; (B) relationship between GVC1 and GM
volume in the right fusiform gyrus; (C) relationship between GVC2 and GM volume in the left cingulate gyrus; (D) relationship between GVC2 and
overall cognitive performance (composite T score) (diabetics: triangles; controls: circles). We presented r2 for the entire model adjusted for age and
sex and group, and P values for the specific effect of Multi-scale GV.
doi:10.1371/journal.pone.0086284.g006
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There are several potential limitations of this study. This was
a cross-sectional, observational study of a small yet well-
characterized cohort. A larger validation study is therefore needed
to determine prospectively whether reducing glycemic variability
might improve outcomes and prevent cardiovascular adverse
events associated with intensive glycemic levels lowering. As CGM
sampling frequency was 5 minutes, we were also unable to study
glycemic fluctuations with periods shorter than 30 minutes. In
addition, the glycemic variability measures are derived from only 3
days of CGM data. To eliminate the influence of edge effect in
EEMD technique and guarantee the accuracy of cycle length for
each GVC, we only selected the GVCs with period less than
24 hours.
In summary, our results indicated that the relationships between
glycemic variability and brain structure and function are time-
scale dependent. The degree of glycemic variability within higher-
frequency rhythms was associated with gray matter atrophy within
the limbic system and temporo-parietal lobes (e.g. cingulum,
insula, and hippocampus) and with worse cognitive performance.
In diabetics, glycemic variability in lower frequency cycles were
associated with worse learning and memory, more depression and
longer DM duration. Implications are that diabetes management
needs to target glycemic ultradian rhythms at specific frequencies
in order to prevent brain atrophy and functional loss in older
diabetic adults. Larger prospective studies are needed to determine
whether time-scale dependent glycemic variability may serve as a
new marker of diabetic complications, and in particular a marker
of DM-related brain damage and subsequent loss of cognitive
function.
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